Physician profile
Michael A Layton
NPI 1255430096
$8,303.77
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $620 · 2021: $1,191 · 2022: $3,934 · 2023: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $3,827.14 | 2019-2022 | |
| Veran Medical Technologies, INC. | $1,504.29 | 2019-2020 | |
| Medical Device Business Services, INC. | $481.48 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $477.16 | 2019-2023 | Imfinzi, Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.56 | 2019-2023 | Ofev |
| Glaxosmithkline, LLC. | $282.44 | 2019-2023 | Trelegy Ellipta |
| Grifols USA, LLC | $218.78 | 2019-2021 | |
| Intuitive Surgical, INC. | $164.59 | 2022-2023 | Da Vinci Surgical System |
| Regeneron Healthcare Solutions, INC. | $132.98 | 2019-2022 | |
| Genzyme Corporation | $102.81 | 2019-2023 | |
| Insmed, INC. | $102.38 | 2019-2022 | |
| Pulmonx Corporation | $91.06 | 2020 | |
| Merck Sharp & Dohme LLC | $86.94 | 2019-2023 | Keytruda |
| Electromed, INC. | $55.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $51.93 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $46.70 | 2019 | |
| Welch Allyn | $43.67 | 2021 | |
| United Therapeutics Corporation | $42.40 | 2021-2022 | |
| Genentech USA, INC. | $39.95 | 2019 | |
| Mylan Specialty L.P. | $37.98 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $37.04 | 2019 | |
| Philips North America LLC | $33.57 | 2019 | |
| Shire North American Group INC | $25.10 | 2019 | |
| Gilead Sciences, INC. | $18.05 | 2021 | |
| Circassia INC. | $14.23 | 2020 | |
| Stryker Corporation | $14.21 | 2019 | |
| Inogen, INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Layton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.